Catalyst
Slingshot members are tracking this event:
Galapagos (GLPG) Doses First Patient in Phase 2 EQUATOR Study Evaluating Filgotinib in Psoriatic Arthritis
- Source Link:
- http://www.glpg.com/docs/view/58e4f68476340-en
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GLPG |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 05, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
First Patient Dosing, Phase 2, Equator, Filgotinib, Psoriatic Arthritis
